InvestorsHub Logo
Followers 20
Posts 1059
Boards Moderated 0
Alias Born 04/01/2013

Re: biotechtrader2020 post# 229930

Monday, 11/25/2019 6:37:52 AM

Monday, November 25, 2019 6:37:52 AM

Post# of 425845
Those peak sales would be numbers MDCO would throw out there, based on competitors and iffy outcome trial results Bp should have been modeling 1.5 billion peak. Based on your logic Amarin should be bought based on 10 billion peak sales. This is an overpay which is worse than 50/50 to pay back much in cash flow over the life of the drug.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News